1. Introduction
===============

Pyran and fused 4*H*-pyran derivatives have attracted a great deal of interest owing to their antimicrobial activity \[[@B1-pharmaceuticals-05-00745],[@B2-pharmaceuticals-05-00745],[@B3-pharmaceuticals-05-00745],[@B4-pharmaceuticals-05-00745],[@B5-pharmaceuticals-05-00745]\], inhibition of influenza, virus sialidases \[[@B6-pharmaceuticals-05-00745]\], mutagenic activity \[[@B7-pharmaceuticals-05-00745]\], activity as antiviral \[[@B8-pharmaceuticals-05-00745]\] and antiproliferation agents \[[@B9-pharmaceuticals-05-00745]\], sex-pheromones \[[@B10-pharmaceuticals-05-00745]\], antitumor \[[@B11-pharmaceuticals-05-00745]\] and anti-inflammatory agents \[[@B12-pharmaceuticals-05-00745]\]. Moreover, pyran derivatives are well known for their antihistaminic activity \[[@B13-pharmaceuticals-05-00745]\]. Also pyrimdines are an important class of compounds and have widespread applications from pharmaceuticals to materials \[[@B14-pharmaceuticals-05-00745]\], with activities such as Tie-2 kinase inhibitors \[[@B15-pharmaceuticals-05-00745]\], HIV-1 inhibitor \[[@B16-pharmaceuticals-05-00745]\], anti-malarial \[[@B17-pharmaceuticals-05-00745]\], adenosine A1 receptor antagonism \[[@B18-pharmaceuticals-05-00745]\], anticancer \[[@B19-pharmaceuticals-05-00745]\], analgesic \[[@B20-pharmaceuticals-05-00745]\], cardiovascular \[[@B21-pharmaceuticals-05-00745]\] and antiallergic activities \[[@B22-pharmaceuticals-05-00745]\]. In view of the important biological properties of the pyran and pyrimidine derivatives as medicinal agents, we report here the synthesis and antimicrobial activities of new naphthopyrano, naphthopyranopyrimidine and naphthopyranotriazolopyrimidine derivatives.

2. Results and Discussion
=========================

Condensation of 6-methoxy-2-naphthol (**1**) with substituted 4-halobenzylidenmalononitriles **2a--c** and/or ethyl 4-halobenzylidenmalonates **2d--f** afforded the corresponding 2-amino-4-(*p*-halophenyl)-7-methoxy-4*H*-naphtho\[2,1-*b*\]pyran-3-carbonitriles **3a--c** and ethyl-2-amino-4-(*p*-halophenyl)-7-methoxy-4*H*-naphtho\[2,1-*b*\]pyran-3-carboxylates **3d--f**, respectively \[[@B23-pharmaceuticals-05-00745],[@B24-pharmaceuticals-05-00745]\] ([Scheme 1](#pharmaceuticals-05-00745-f001){ref-type="scheme"}).

![Synthesis of naphthopyran derivatives **3a--f**.](pharmaceuticals-05-00745-g001){#pharmaceuticals-05-00745-f001}

The structure of compounds **3a--f** were established by spectral data. The IR spectrum of compounds **3a--f** showed absorptions at 3,466--3,350, 3,346--3,314 cm^−1^ (NH~2~), 3,192--3,000 cm^−1^ (CH-aromatic), 2,950--2,900 (CH-aliphatic), 2,200--2,192 cm^−1^ (C≡N), 1,682--1,670 cm^−1^ (C=O). The ^1^H-NMR of compounds **3a--f** showed chemical shifts δ~H~ at 3.75--3.78 (s, 3H, OCH~3~), 5.27--5.530 (s, 1H, pyran CH), 6.98--7.21 (br, 2H, NH~2~, exchangeable by D~2~O) while the ^13^C-NMR of compound **3b** showed δ~C~ at 56.5 (OCH~3~), 28.4 (C-4), 117.1 (C≡N) and compound **3e** showed chemical shifts δ~C~ at 13.1 (CH~3~-ester), 28.4 (C-4), 56.5 (OCH~3~), 62.5 (CH~2~-ester) and 172.2 (CO).

Treatment of **3b** with Ac~2~O gave two products, depending on the reaction time; one product was identified as 2-acetylamino-7-methoxy-4-(*p*-chlorophenyl)-4*H*-naphtho\[2,1-*b*\]pyran-3-carbonitrile (**4**, 1/2 hour), while the other was identified as 10,11-dihydro-3-methoxy-9-methyl-12-(*p*-chlorophenyl)-12*H*-naphtho\[2,1-*b*\]pyrano-\[2,3-*d*\]pyrimidine-11-one (**5**, 3 hours). Support for structure **5** was obtained by its independent synthesis by the reaction of **3e** with CH~3~CN in the presence of dry HCl gas \[[@B25-pharmaceuticals-05-00745]\]. Reaction of **3b** with benzoyl chloride gave the pyranopyrimidin-11-one derivative **6**, while with formamide afforded 11-amino-3-methoxy-12-(*p*-chlorophenyl)-12*H*-naphtho\[2,1-*b*\]pyrano\[2,3-d\]pyrimidine **7** ([Scheme 2](#pharmaceuticals-05-00745-f002){ref-type="scheme"}).

![Synthesis of naphthopyran and naphthopyranpyrimidine derivatives **4--7**.](pharmaceuticals-05-00745-g002){#pharmaceuticals-05-00745-f002}

The structure of compounds **4**--**7** were established from their spectral data. The IR spectrum of compound **4** showed absorptions at 3,400 (NH), 2,202 cm^−1^ (CN), 1,612 cm^−1^ (C=O), while compound **5** showed absorptions at 3,464 (NH), 1,650 cm^−1^ (C=O) and compound **7** showed υ at 3,458, 3,380 (NH~2~). The ^1^H-NMR of compounds **4--7** showed chemical shifts δ~H~ at 3.78--3.82 (s, 3H, OCH~3~), 5.66--5.70 (s, 1H, pyran CH). The mass spectra of compounds **6** and **7** provided additional evidence for the proposed structures.

Reaction of **3b** with triethyl orthoformate gave the corresponding 2-ethoxymetheneamino derivative **8**. Hydrazinolysis of **8** in EtOH at room temperature yielded 10-amino-10,11-dihydro-11-imino-3-methoxy-12-(*p-*chlorophenyl)-12*H*-naphtho\[2,1-*b*\]pyrano\[2,3-*d*\]pyrimidine (**9**). During treatment of **8** with phenylhydrazine, an nonisolable addition product **A** was formed first, followed by elimination of the nonisolable ethyl formatephenylhydrazone to give the enaminonitrile **3b**. Ammonolysis of **8** in MeOH at room temperature afforded compound **7** and aminolysis of **8** with methylamine and/or dimethylamine gave the corresponding 10-methyl-pyranopyrimidine and *N,N*-dimethylamino-methylene derivatives **10** and **11**, respectively ([Scheme 3](#pharmaceuticals-05-00745-f003){ref-type="scheme"}).

The structure of compounds **8--11** were established from their spectral data. The IR spectrum of compound **8** showed absorptions at 2,203 cm^−1^ (C≡N), while compound **9** showed υ at 3,316, 3,270 (NH~2~), 3,209 cm^−1^ (NH) and compound **11** showed an absorption at 2,204 cm^−1^ (C≡N). The ^1^H-NMR of compounds **8--11** showed chemical shifts δ~H~ at 3.77--3.80 (s, 3H, OCH~3~) and 5.29--5.58 (s, 1H, pyran CH).

![Reaction of **3b** with triethyl orthoformate and of ammionium derivatives.](pharmaceuticals-05-00745-g003){#pharmaceuticals-05-00745-f003}

Reaction of **9** with formic acid or triethyl orthoformate, acetylchloride and benzoyl chloride afforded the corresponding triazolopyrimidine derivatives **12--14**, while cyclocondensation of **9** with ethyl cyanoacetate gave the corresponding 2-cyanomethyl derivative **15**. Treatment of **9** with ethyl chloroformate in dry benzene affored traizolo-2-one derivative **16**. Reaction of **9** with benzaldehyde gave 10-benzalamino-10,11-dihydro-11-imino-3-methoxy-12-(*p*-chlorophenyl)-12*H*-naphtho-\[2,1-*b*\]-pyrano\[2,3-*d*\]pyrimidine (**17**) instead of the expected triazolopyrimidine derivative **14** ([Scheme 4](#pharmaceuticals-05-00745-f004){ref-type="scheme"}).

![Synthesis of naphthopyrantriazolopyridimide derivatives **12--17**.](pharmaceuticals-05-00745-g004){#pharmaceuticals-05-00745-f004}

The structure of compounds **12--17** were established from their spectral data. The IR spectrum of compound **15** showed an absorption at 2,200 cm^−1^ (C≡N), compound **16** showed absorptions at 3,200 cm^−1^ (NH) and 1,638 cm^−1^ (C=O), while compound **17** showed absorptions at 3,261 cm^−1^ (NH), and 1,621 cm^−1^ (C=N). The ^1^H-NMR of compounds **12--17** showed chemical shifts δ~H~ at 3.78--3.80 (s, 3H, OCH~3~), 526--5.66 (s, 1H, pyran CH), 8.63--9.64 (s, 1H, pyrimidine CH).

The antimicrobial activity of the newly synthesized compounds **3--17** was evaluated against the bacterial strains *Staphylococcus aureus (NCTC-7447)*, *Bacillus cereus (ATCC-14579)*, *Escherichia coli (NCTC-10410)*, *Serratia marcescens (IMRU-70)*and the fungal strains *Aspergillus fumigatus (MTCC-3008)*, and *Candida albicans* (MTCC-227) by the disk diffusion method \[[@B26-pharmaceuticals-05-00745],[@B27-pharmaceuticals-05-00745]\]. Ampicillin and ketoconazole were used as standard drugs for the bacteria and fungi, respectively. Preliminary screening of the naphthopyran derivatives and standard drugs was performed at fixed concentrations of 500 μg/mL. Inhibition was recorded by measuring the diameter of the inhibition zone at the end of 24 hours for bacteria and 72 hours for fungi. Each experiment was repeated twice. Based on the results of zone of inhibition, the minimum inhibitory concentration (MIC) of compounds **3--17** against all bacterial and fungal strains was determined by the liquid dilution method. Stock solutions of the tested compounds with 500, 250, 200, 100, 50, 25, 12.5, and 6.25 μg/mL concentrations were prepared with DMSO as solvent. The solutions of standard drugs, ampicillin and ketoconazole, were prepared in the same concentrations. The minimum inhibitory concentration at which no growth was observed was taken as the MIC value ([Table 1](#pharmaceuticals-05-00745-t001){ref-type="table"}). The comparison of the MICs (μg/mL) of potent compounds and standard drugs against tested strains are presented in [Table 1](#pharmaceuticals-05-00745-t001){ref-type="table"}. Investigation of the antibacterial screening data showed that some of the compounds were active against all four pathogenic bacteria. Ethyl 2-amino-4-(*p*-chlorophenyl)naphthopyrane-3-carboxylate (**3e**), triazolopyrimidine derivative **12**, 2-methyl-triazolopyrimidine derivative **13**, 2-phenyl-triazolopyrimidine derivative **14** and, 2-oxa-triazolopyrimidine derivative **16** exhibited good activity against *S. aureus*. Similarly 2-amino-3-cyano-4-(*p*-flourophenyl)naphthopyran (**3c**), 2-methyltriazolopyrimidine derivative **14**, triazolopyrimidine derivative **12**, triazolopyrimidine 2-ethanenitrile derivative **15** and 2-oxa-triazolopyrimidine derivative **16** exhibited good activity against *B. cereus* and 2-amino-3-cyano4-(*p*-bromophenyl)naphthopyran (**3a**), 2-amino-3-cyano-4-(*p*-chlorophenyl)naphthopyran (**3b**), 2-amino-3-cyano-4-(*p*-flourophenyl)naphthopyran **3c**, ethyl 2-amino-4-(*p*-chlorophenyl)naphthopyran-3-carboxylate (**3e**), 2-methyl-triazolopyrimidine derivative **13** and triazolopyrimidine 2-ethanenitrile derivative **16** exhibited good activity against *E. coli*, while 2-amino-3-cyano-4-(*p*-bromo/chloro/fluorophenyl)naphthopyran derivatives **3a--c**, triazolopyrimidine derivative **12**, 2-phenyltriazolopyrimidine derivative **14** and 2-oxatriazolopyrimidine derivative **16** exhibited good activity against *S. marcescens*. Aminoimino derivative **9** was inactive against *S. aureus*, while the pyranpyrimidin-11-one **6** and 10-benzalamino-pyranopyrimidine derivative **17** was inactive against *B. cereus*, the compounds ethyl 2-amino-4-(*p*-chlorophenyl)naphthopyrane-3-carboxylate (**3e**), 11-amino-pyranopyrimidine **7** and 2-ethoxy-methyleneamino derivative **8** was inactive against *E. coli*, and the 2-acetylamino-pyranopyrimidine compound **4** was inactive against *S. marcescens*. The remaining compounds showed moderate to weak antibacterial activity.

pharmaceuticals-05-00745-t001_Table 1

###### 

Antimicrobial activity of the new compounds*.*

  Compounds          Minimum inhibitory concentration (MIC) in μg/mL                                
  ------------------ ------------------------------------------------- ------ ------ ------ ------- -------
  **3a**             100                                               100    25     50     100     100
  **3b**             125                                               200    50     50     125     100
  **3c**             100                                               50     25     50     50      50
  **3d**             250                                               200    500    500    250     100
  **3e**             25                                                100    50     100    25      50
  **3f**             500                                               500    \-     125    250     500
  **4**              500                                               250    250    100    500     \-
  **5**              100                                               125    \-     500    \-      250
  **6**              100                                               \-     100    250    500     500
  **7**              500                                               200    \-     200    \-      250
  **8**              250                                               200    500    500    250     100
  **9**              \-                                                500    \-     100    500     500
  **10**             500                                               250    100    250    250     500
  **11**             \-                                                500    250    \-     \-      500
  **12**             25                                                25     50     25     100     50
  **13**             25                                                50     25     50     50      500
  **14**             50                                                100    100    25     25      50
  **15**             100                                               25     25     125    100     500
  **16**             50                                                25     50     50     125     100
  **17**             500                                               \-     250    500    \-      \-
  **Ampcillin**      6.25                                              6.25   6.25   6.25   6.25    6.25
  **Ketoconazole**   \-                                                \-     \-     \-     31.25   31.25

The antifungal results ([Table 1](#pharmaceuticals-05-00745-t001){ref-type="table"}) revealed that the synthesized compounds showed variable degrees of inhibition against the tested fungi. The compounds 2-amino-3-cyano-4-(*p*-fluorophenyl)naphthopyran (**3c**), ethyl 2-amino-4-(*p*-chlorophenyl)naphthopyran-3-carboxylate (**3e**), and 2-phenyltriazolopyrimidine **14** possessed good antifungal activity against *A. fumigatus*and *C. albicans*, while the compounds 9-methyl-pyranopyrimidine **5**, 11-amino-pyranopyrimidine **7**, *N*,*N*-dimethylaminomethylene derivative **11** and 10-benzalaminopyranopyrimidine **17** were inactive against *A. fumigates*, and the 2-acetylaminopyranopyrimidine **4** and 10-benzalaminopyranopyrimidine **17** were inactive against *C. albicans.* The remaining compounds showed moderate to weak antifungal activity.

3. Experimental
===============

3.1. General
------------

Melting points were determined on a Stuart melting point apparatus and are uncorrected. IR spectra (ν, cm^−1^) were recorded in KBr using a FT-IR 5300 spectrometer and aPerkin Elmer spectrum RXIFT-IR system. The ^1^H-NMR at (300 MHz) and ^13^C-NMR spectra (75 MHz) were recorded in DMSO-d~6~ on a Varian Mercury VX-300 NMR spectrometer. Chemical shifts (δ) are referred to that of the solvent. Mass spectra were measured on a Shimadzu GMMS-QP-1000 EX mass spectrometer at 70 eV. The elemental analyses were performed at the Micro Analytical Center, Cairo University, Egypt.

3.2. General Procedure: Synthesis of 4H-Pyran Derivatives ***3a--f***
---------------------------------------------------------------------

A mixture of substituted 4-halobenzylidenmalononitriles **2a**--**c** (10 mmol) and/or ethyl 4-halobenzylidenmalonates **2d**--**f** (10 mmol), 6-methoxy-2-naphthol (**1**) (0.17 g, 10 mmol) and piperidine (0.5 mL) in absolute EtOH (50 mL) was heated until precipitation was completed. The precipitate was collected by filtration and recrystallized from dioxane and EtOH/benzene respectively.

*2-Amino-4-(p-bromophenyl)-7-methoxy-4H-naphtho\[2,1-b\]pyrane-3-carbonnitrile*(**3a**). White crystals (dioxane); yield 88%, mp 260--262 °C; IR: 3,454, 3,315 (NH~2~), 3,182 (CH-aromatic), 2,950 (CH-aliphatic), 2,192 (C≡N), 1,658 (C=C). ^1^H-NMR δ: 3.78 (s, 3H, OCH~3~), 5.27 (s, 1H, pyran CH), 6.98 (br, 2H, NH~2~, exchangeable by D~2~O), 7.06--7.79 (m, 9H, Ar-H). Anal. Calcd. for C~21~H~15~BrN~2~O~2~ (406.03): C, 61.90; H, 3.90; N, 6.84%. Found: C, 61.93; H, 3.71; N, 6.88%.

*2-Amino-4-(p-chlorophenyl)-7-methoxy-4H-naphtho\[2,1-b\]pyrane-3-carbonnitrile*(**3b**). White crystals (dioxane); yield 90%, mp 246--248 °C; IR: 3,358, 3,314 (NH*~2~*), 3,186 (CH-aromatic), 2,932 (CH-aliphatic), 2,198 (C≡N), 1,660 (C=C). ^1^H-NMR δ: 3.77 (s, 3H, OCH~3~), 5.28 (s, 1H, pyran CH), 6.99 (br, 2H, NH~2~, exchangeable by D~2~O), 7.06--7.79 (m, 9H, Ar-H). ^13^C-NMR δ: 28.4 (C-4), 56.50 (OCH~3~), 59.1 (C-3), 105.9 (C-7), 117.1 (C≡N), 118.6 (C-5), 118.9 (C-9), 121.3 (C-4a), 123.6 (C-10), 127.1 (C-6), 128.2 (C-5a, C-8a), 128.7, 129.7, 131.3, 136.6, 143.8 (Ar), 150.2 (C-10), 157.2 (C-8), 160.2 (C-2). Anal. Calcd. for C~21~H~15~ClN~2~O~2~ (362.08): C, 69.52; H, 4.17; N, 7.72%. Found: C, 69.50; H, 4.15; N, 7.70%.

*2-Amino-4-(p-flouroophenyl)-7-methoxy-4H-naphtho\[2,1-b\]pyran-3-carbonitrile*(**3c**). White crystals (dioxane); yield 86%, mp 255--257 °C; IR: 3,466, 3,318 (NH~2~), 3,192 (CH-aromatic), 2,900 (CH-aliphatic), 2,200 (C≡N), 1,662 (C=C). ^1^H-NMR δ: 3.75 (s, 3H, OCH~3~), 5.30 (s, 1H, pyran CH), 7.01 (br, 2H, NH~2~, exchangeable by D~2~O), 7.08--8.31 (m, 9H, Ar-H). Anal. Calcd for C~21~H~15~FN~2~O~2~ (346.11): C, 72.82; H, 4.37; N, 8.09%. Found: C, 72.80; H, 4.35; N, 7.99%.

*Ethyl 2-amino-4-(p-bromophenyl)-7-methoxy-4H-naphtho\[2,1-b\]pyran-3-carboxylate*(**3d**). Colourless needle-like crystals (ethanol/benzene); yield 79%, mp 167--169 °C: IR: 3,350, 3,324 (NH~2~), 3,000 (CH-aromatic), 2,944 (CH-aliphatic), 1,682 (C=O), 1,618 (C=C). ^1^H-NMR δ: 1.21 (t, 3H, CH~3~, *J* = 7.1 Hz), 3.78 (s, 3H, OCH~3~), 4.04 (q, 2H, CH~2~, *J* = 7.1 Hz), 5.42 (s, 1H, pyran CH), 7.21(br, 2H, NH~2~, exchangeable by D~2~O), 7.28--7.86 (m, 9H, Ar-H). Anal. Calcd. for C~23~H~20~BrNO~4~ (453.06): C, 60.81; H, 4.44; N, 3.08%. Found: C, 60.80; H, 4.41; N, 3.03%.

*Ethyl 2-amino-4-(p-chlorophenyl)-7-methoxy-4H-naphtho\[2,1-b\]pyran-3-carboxylate*(**3e**). Colourless needle crystals, (ethanol/benzene); yield 82%, mp 172--174 °C: IR: 3,458, 3,324 (NH~2~), 3,010 (CH-aromatic), 2,970 (CH-aliphatic), 1,670 (C=O), 1,622 (C=C). ^1^H-NMR δ: 1.38 (t, 3H, CH~3~, *J* *=* 7.1 Hz), 3.80 (s, 3H, OCH~3~), 4.31 (q, 2H, CH~2~, *J* *=* 7.1 Hz), 5.40 (s, 1H, pyran CH), 6.24 (br, 2H, NH~2~, exchangeable by D~2~O), 6.89--7.75 (m, 9H, Ar-H). ^13^C-NMR δ: 13.1 (CH~3~-ester), 28.4 (C-4), 56.5 (OCH~3~), 59.1 (C-3), 62.5 (CH~2~-ester), 105.9 (C-7), 118.6 (C-5), 118.9 (C-9), 121.3 (C-4a), 123.6 (C-10), 127.1 (C-6), 128.2 (C-5a, C-8a), 128.7, 129.7, 131.3, 136.6, 143.8 (Ar),150.2 (C-10), 157.2 (C-8), 160.2 (C-2), 172 (C=O). Anal. Calcd. for C~23~H~20~ClNO~4~ (409.11): C, 67.40; H, 4.92; N, 3.42%. Found: C, 67.38; H, 4.90; N, 3.39%.

*Ethyl 2-amino-4-(p-flouophenyl)-7-methoxy-4H-naphtho\[2,1-b\]pyran-3-carboxylate*(**3f**). Colourless needle-like crystals (ethanol/benzene); yield 77%, mp 186--188 °C; IR: 3,422, 3,346 (NH~2~), 3,192 (CH-aromatic), 2,900 (CH-aliphatic), 1,682 (CO), 1,600 (C=C). ^1^H-NMR δ: 1.39 (t, 3H, CH~3~, *J* *=* 7.1 Hz), 3.78 (s, 3H, OCH~3~), 4.30 (q, 2H, CH~2~, *J* *=* 7.1 Hz), 5.54 (s, 1H, pyran CH), 6.36 (br, 2H, NH~2~, exchangeable by D~2~O), 7.05--8.06 (m, 9H, Ar-H). Anal. Calcd. for C~23~H~20~FNO~4~ (393.14): C, 70.20; H, 5.10; N, 3.52%. Found: C, 70.22; H, 5.12; N, 3.56%.

*Synthesis of 2-acetylamino-7-methoxy-4-(p-chlorophenyl)-4H-naphtho\[2,1-b\]pyran-3-carbonitrile*(**4**)*.* A solution of **3b** (0.36 g, 10 mmol) in Ac~2~O (20 mL) was heated under reflux for 30 min. The solid product formed was filtered off and washed with cold EtOH, The solid obtained was filtered off and recrystallized from EtOH. Pale yellow crystals, yield 89%, mp 175--177 °C; IR: 3,400 (NH), 3,122 (CH-aromatic), 2,940 (CH-aliphatic), 2,202 (C≡N), 1,612 (C=O). ^1^H-NMR δ: 2.26 (s, 3H, CH~3~), 3.82 (s, 3H, OCH~3~), 5.70 (s, 1H, pyran CH), 7.22--7.83 (m, 9H, Ar-H), 12.49 (br, 1H, NH, exchangeable by D~2~O). Anal. Calcd. for C~23~H~17~ClN~2~O~3~ (404.09): C, 68.23; H, 4.23; N, 6.92%. Found: C, 68.20; H, 4.19; N, 6.90%.

*Synthesis of 10,11-dihydro-3-methoxy-9-methyl-12-(p-chlorophenyl)-12H-naphtho-\[2,1-b\]pyrano\[2,3-d\]pyrimidine-11-one*(**5**). [Method A]{.ul}: A solution of **3b** (0.36 g, 10 mmol) in Ac~2~O (20 mL) was heated under reflux for 3 hours. The precipitate was filtered off, washed with cold EtOH. The solid obtained was filtered off and recrystallized from DMF; [Method B]{.ul}: Gaseous dry HCl was bubbled through the mixture of **3e** (0.40 g, 10 mmol) and CH~3~CN (30 mL) for 4--6 hours. The reaction mixture was poured into ice water and made alkaline with 10% aqueous ammonium hydroxide to give **5**. White crystals, yield 85%, mp 290--292 °C: IR: 3,464 (NH), 3,001 (CH-aromatic), 2,980 (CH-aliphatic), 1,650 (C=O), 1,620 (C=C). ^1^H-NMR δ: 2.28 (s, 3H, CH~3~), 3.78 (s, 3H, OCH~3~), 5.66 (s, 1H, pyran CH), 6.89--8.01 (m, 10H, Ar-H and NH). Anal. Calcd. for C~23~H~17~ClN~2~O~3~ (404.09): C, 68.23; H, 4.23; N, 6.92%. Found: C, 68.20; H, 4.19; N, 6.90%.

*Synthesis of 10,11-dihydro-3-methoxy-9-phenyl-12-(p-chlorophenyl)-12H-naphtho\[2,1-b\]-pyrano\[2,3-d\]pyrimidine-11-one*(**6**). A solution of **3b** (0.36 g, 10 mmol) in benzoyl chloride (20 mL) was heated under reflux for 6 hours. The excess of benzoyl chloride was removed under reduced pressure and the residue was poured into cold water. The precipitate was collected by filtration, washed with CCl~4~ (10 mL) to remove the formed benzoic acid and the residue was dried. The solid obtained was filtered off and recrystallized from DMF. Yellow crystals, yield 80%, mp \> 360 °C; IR: 3,433 (NH), 3,012 (CH-aromatic), 2,892 (CH-aliphatic), 1,640 (C=O), 1,572 (C=C). MS *m/z*(%) = 466 (M+, 47.7), 326 (100), 250 (16.4), 129 (10.9). Anal. Calcd. for C~28~H~19~ClN~2~O~3~ (466.11): C, 72.03; H, 4.10; N, 6.01%. Found: C, 72.01; H, 4.02; N, 5.88%.

*Synthesis of 11-amino-3-methoxy-12-(p*-chlorophenyl*))-12H-naphtho\[2,1-b\]pyrano\[2,3-d\]pyrimidine*(**7**). [Method A]{.ul}: A solution of **3b** (0.36 g, 10 mmol) in formamide (20 mL) was heated under reflux for 6 hours. The solid obtained was filtered off and recrystallized from benzene; [Method B]{.ul}: Gaseous NH~3~ was bubbled through **8** (0.41 g, 10 mmol) in MeOH for 1 hour. The solid formed was collected to give **7**. White crystals (benzene); yield 75%, mp 317--319 °C; IR: 3,458, 3,380 (NH~2~), 3,174 (CH-aromatic), 2,901 (CH-aliphatic), 1,658 (C=C). MS *m/z*(%) = 389 (M+, 25.6), 249 (100), 223 (10.1), 181 (1.1). Anal. Calcd. for C~22~H~16~ClN~3~O~3~ (389.09): C, 67.78; H, 4.14; N, 10.78%. Found: C, 67.72; H, 4.10; N, 10.74%.

*Synthesis of 2-ethoxymethyleneamino-7-methoxy-4-(p-chlorophenyl)-4H-naphtho-\[2,1-b\]pyrane-3-carbonitrile*(**8**)*.* A mixture of **3b** (0.36 g, 10 mmol) and triethyl orthoformate (2 mL) in acetic anhydride (10 mL) was refluxed for 2 hours. After cooling, the precipitated product was filtered off and washed several times with cold EtOH. The solid obtained was filtered off and recrystallized from benzene. Colourless crystals, yield 77%, mp 211--213 °C; IR: 2,980 (CH-aromatic), 2,835 (CH-aliphatic), 2,204 (CN), 1,612 (C=N). ^1^H-NMR δ: 1.27 (t, 3H, CH~3~, *J* = 7.1 Hz), 3.78 (s, 3H, OCH~3~), 4.40 (q, 2H, CH~2~, *J* = 7.1 Hz), 5.58 (s, 1H, pyran CH), 7.24--785 (m, 9H, Ar-H), 8.67 (s, 1H, N = CH). Anal. Calcd. for C~24~H~19~ClN~2~O~3~ (418.11): C, 68.82; H, 4.57; N, 6.69%. Found: C, 68.80; H, 4.51; N, 6.62%.

3.3. General Procedure: Synthesis of Pyranopyrimidine Derivatives ***9*** and ***10***
--------------------------------------------------------------------------------------

A mixture of **8** (0.41 g, 10 mmol), hydrazine hydrate (5 mL, 99%) or methylamine (10 mmol) in absolute ethanol (50 mL) was stirred for 1 hour at room temperature. The solid obtained was filtered off and recrystallized from dioxane.

*10-Amino-10,11-dihydro-11-imino-3-methoxy-12-(p-chlorophenyl)-12H-naphtho\[2,1-b\]pyrano\[2,3-d\]pyrimidine* (**9**). White crystals, yield 81%, mp 256--258 °C; IR: 3,316, 3,270 (NH~2~), 3,209 (NH), 2,936 (CH-aromatic), 2,899 (CH-aliphatic), 1,647 (C=N). ^1^H-NMR δ: 3.80 (s, 3H, OCH~3~), 5.66 (s, 1H, pyran CH), 5.87 (br, 2H, NH~2~, exchangeable by D~2~O), 7.15--7.79 (m, 10H, Ar-H and NH), 8.04 (s, 1H, pyrimidine CH). Anal. Calcd. for C~22~H~17~ClN~4~O~2~ (404.10): C, 65.27; H, 4.23; N, 13.84%. Found: C, 65.25; H, 4.20; N, 13.82%.

*10,11-Dihydro-11-imino-3-methoxy-10-methyl-12-(p-chlorophenyl)-12H-naphtho\[2,1-b\]pyrano\[2,3-d\]pyrimidine* (**10**). White crystals, yield 80%, mp 255--257 °C; IR: 3,376 (NH), 3,006 (CH-aromatic), 2,980, 2,830 (CH-aliphatic), 1,620 (C=N). ^1^H-NMR δ: 3.32 (s, 3H, N-CH~3~), 3.77 (s, 3H, OCH~3~), 5.29 (s, 1H, pyran CH), 6.98--7.80 (m, 10H, Ar-H and NH), 8.01 (s, 1H, pyrimidine CH). Anal. Calcd for C~23~H~18~ClN~3~O~2~ (403.11): C, 68.40; H, 4.49; N, 10.40%. Found: C, 68.20; H, 4.41; N, 10.38%.

*Synthesis of 7-methoxy-2-(N,N-dimethylaminomethylene)-4-(p-chlorophenyl)-4H-naphtho\[2,1-b\]-pyrane-3-carbonitrile* (**11**)*.* A mixture of **8** (0.41 g, 10 mmol) and dimethylamine (5 mL) in ethanol was stirred for 1 hour. The white solid formed was filtered, washed with cold EtOH and recrystallized from benzene. White crystals, yield 79%, mp 218--220 °C; IR: 2,924 (CH-aliphatic), 2,190 (C≡N), 1,616 (C=N). ^1^H-NMR δ: 2.97 (s, 3H, N-CH~3~), 3.13 (s, 3H, N-CH~3~), 3.78 (s, 3H, OCH~3~), 5.40 (s, 1H, pyran CH), 7.18--7.83 (m, 9H, Ar-H), 8.42 (s, 1H, N=CH). Anal. Calcd. for C~24~H~20~ClN~3~O~2~ (417.12): C, 68.98; H, 4.82; N, 10.06%. Found: C, 68.81; H, 4.66; N, 9.98%.

3.4. General Procedure: Synthesis of Pyranotriazolopyrimidine Derivatives ***12--16***
--------------------------------------------------------------------------------------

A mixture of **9** (0.40 g, 10 mmol), triethyl orthoformate, formic acid, acetyl chloride or benzoyl chloride (0.01 mol) in dry benzene (20 mL), was refluxed for 3 hours. The solid obtained was filtered off and recrystallized from dioxane.

*11-Methoxy-14-(p-chlorophenyl)-14H-naphtho\[2,1-b\]pyrano\[3,2-b\]\[1,2,4\]triazolo\[1,5-c\]pyrimidine* (**12**). White crystals, yield 80%, mp 260--262 °C; IR: 3,064 (CH-aromatic), 2,984, 2,844 (CH-aliphatic), 1,602 (C=C). ^1^H-NMR δ: 3.78 (s, 3H, OCH~3~), 5.42 (s, 1H, pyran CH), 7.00--7.91 (m, 9H, Ar-H), 8.63 (s, 1H, pyrimidine CH), 9.51 (s, 1H, triazolo CH). Anal. Calcd. for C~23~H~15~ClN~4~O~2~(414.09): C, 66.59; H, 3.61; N, 13.50%. Found: C, 66.50; H, 3.53; N, 13.10%.

*2-Methyl-11-methoxy-14-(p-chlorophenyl)-14H-naphtho\[2,1-b\]pyrano\[3,2-e\]\[1,2,4\]triazolo\[1,5-c\]pyrimidine*(**13**). White crystals, yield 85%, mp 283--285 °C; IR: 3,074 (CH-aromatic), 2,936, (CH-aliphatic), 1,622 (C=C). ^1^H-NMR δ: 2.40 (s, 3H, CH~3~), 3.79 (s, 3H, OCH~3~), 5.43 (s, 1H, pyran CH), 6.99--7.99 (m, 9H, Ar-H), 9.51 (s, 1H, pyrimidine CH). Anal. Calcd. for C~24~H~17~ClN~4~O~2~ (428.10): C, 67.21; H, 3.96; N, 13.06%. Found: C, 67.10; H, 3.66; N, 12.99%.

*2-Phenyl-11-methoxy-14-(p-chlorophenyl)-14H-naphtho\[2,1-b\]pyrano\[3,2-e\]\[1,2,4\]triazolo\[1,5-c\]pyrimidine*(**14**)*.* Pale yellow crystals, yield 70%, mp 281--283 °C; IR: 3,058 (CH-aromatic), 2,920 (CH-aliphatic), 1,626 (C=C). ^1^H-NMR δ: 3.78 (s, 3H, OCH~3~), 5.32 (s, 1H, pyran CH), 7.03--7.91 (m, 14H, Ar-H), 8.70 (s, 1H, pyrimidine CH). Anal. Calcd for C~29~H~19~ClN~4~O~2~ (490.12): C, 70.95; H, 3.87; N, 11.41%. Found: C, 70.65; H, 3.66; N, 11.27%.

*Synthesis of 11-methoxy-14-(p-chlorophenyl)-14H-naphtho\[2,1-b\]pyrano\[3,2-e\]\[1,2,4\]triazolo\[1,5-c\]pyrimidine-2-ethanenitrile*(**15**). A mixture of **9** (0.40 g, 10 mmol) with ethyl cyanoacetate (10 mmol) in absolute ethanol (30 mL), was refluxed for 3 hours. The solid obtained was filtered off and recrystallized from dioxane. White crystals, yield 70%, mp 291--293 °C; IR: 2,934 (CH-aliphatic), 2,200 (C≡N), 1,604 (C=C). ^1^H-NMR δ: 3.80 (s, 3H, OCH~3~), 4.50 (s, 2H, CH~2~), 5.40 (s, 1H, pyran CH), 6.99--7.94 (m, 9H, Ar-H), 9.64 (s, 1H, pyrimidine CH). Anal. Calcd. for C~25~H~16~ClN~5~O~2~ (453.10): C, 66.16; H, 3.52; N, 15.42%. Found: C, 66.01; H, 3.41; N, 15.23%.

*Synthesis of 11-methoxy-14-(p-chlorophenyl)-2oxa-2H,3H,14H-naphtho\[2,1-b\]pyrano\[3,2-e\]\[1,2,4\]-triazolo\[1,5-c\]pyrimidine* (**16**). A mixture of **9** (0.40 g, 10 mmol) with ethyl chloroformate (10 mmol) in dry benzene (30 mL) was refluxed for 1 hour. The solid obtained was filtered off and recrystallized from dioxane. White crystals, yield 76%, mp 310--312 °C: IR: 3,200 (NH), 2,988, 2,930 (CH-aliphatic), 1,638 (C=O), ^1^H-NMR δ: 3.80 (s, 3H, OCH~3~), 5.28 (s, 1H, pyran CH), 6.80--7.88 (m, 10H, Ar-H and NH), 9.64 (s, 1H, pyrimidine CH). Anal. Calcd. for C~23~H~15~ClN~4~O~3~ (431.08): C, 64.12; H, 3.50; N, 13.00%. Found: C, 63.86; H, 3.45; N, 12.81%.

*Synthesis of 10-benzalamino-10,11-dihydro-11-imino-3-methoxy-12-(p-chlorophenyl)12H-naphtho-\[2,1-b\]pyrano-\[2,3-d\]pyrimidine* (**17**). A mixture of **9** (0.40 g, 1.0 mmol), with benzaldehyde (10 mmol), piperidine (0.5 mL) and dioxane (30 mL) was refluxed for 6 hours. The precipitate was filtered off and washed several times with cold EtOH. The solid was recrystallized from dioxane. White crystals, yield 71%, mp 255--257 °C; IR: 3,261 (NH), 2,988, 2,930 (CH-aliphatic), 1,652 (C=N), ^1^H-NMR δ: 3.79 (s, 3H, OCH~3~), 5.66 (s, 1H, pyran CH), 6.80--7.88 (m, 15H, Ar-H and NH), 8.27 (s, 1H, N=CH), 9.64 (s, 1H, pyrimidine CH). Anal. Calcd. for C~29~H~21~ClN~4~O~2~(492.14): C, 70.66; H, 4.29; N, 11.37%. Found: C, 70.54; H, 4.04; N, 11.21%.

3.5. Antimicrobial Assay
------------------------

Inoculums of the bacterial and fungal culture were prepared. To a series of tubes containing 1 mL each of naphthopyran compound solution with different concentrations and 0.2 mL of the inoculums was added. A further 3.8 mL of sterile water was added to each of the test tubes. These test tubes were incubated for 24 hours at 37 °C and observed for the presence of turbidity. This method was repeated by changing naphthopyran compounds for the standard drugs ampicillin and ketoconazole for comparison.

4. Conclusions
==============

Our interest in the synthesis of such compounds was to focus on their study as antimicrobial agents as a part of our program which aimed at the development of new heterocyclic compounds as more potent antimicrobial agents. In this paper we revealed the synthesis of some new naphthopyran, naphthopyranopyrimidine and naphthopyranotriazolopyrimidine derivatives and the antimicrobial evaluation of all the novel compounds. The structures of these compounds were elucidated on the basis of IR, ^1^H-NMR, ^13^C-NMR and MS data. Evaluation of the new compounds established that **3a--e**, **12**--**14** and **16** showed improved antimicrobial activity.
